At the beginning of the year, the start-up METHYS Dx, specialized in the development of personalized medicine in oncology through non-invasive monitoring techniques, has attracted attention. Supported by Erganeo since 2016, METHYS Dx has been in the spotlight through several news articles :

The 100 Start-ups to Invest in 2024

Challenges magazine has nominated METHYS Dx among the 100 start-ups to invest in 2024, in the Biotech category.

Watch the start-up video

Learn more about the start-up

                                                               _____________________________________________

Healthtech Trophy 2024

At the end of March, the start-up, specialized in biomarkers, was a finalist in the "Medical Diagnosis" category of the Healthtech Trophy 2024 awarded by France Biotech.

View the finalists

                                                               _____________________________________________

Joint Interview with Valérie Taly and Magalie Droniou

CEO Valérie Taly and General Manager Magalie Droniou were interviewed by Le Jaune et La Rouge newspaper, sharing the company's beginnings, challenges, and future prospects.

Read the interview

                                                             _____________________________________________

Inventors' Awards 2024 by Le Point

In March, Valérie Taly, CEO of the start-up, was mentioned in the 2024 Inventors' Awards by Le Point magazine, in the "biotech" category.

View the 2024 awards

This series of recognitions marks a promising start for the start-up, which is considering a fundraising round for the commercialization of its first products for monitoring cancer patients, as well as for the development of its medical diagnostic products.